Vivimed Labs Limited — Important, 14-02-2025: Financial Result Updates

**Consolidated Financials:** Vivimed Labs Limited posted consolidated revenue from operations of ₹365.77 crore for the quarter ended December 31, 2024, reflecting a significant increase year-over-year from ₹247.99 crore, marking a revenue growth of approximately 47.3%. Factors contributing to this growth could include increased demand for their pharmaceutical products as well as strategic market expansions.

**Profit and EPS:** The consolidated net profit for the quarter was a loss of ₹59.75 crore, compared to a loss of ₹51.41 crore in the same quarter of the previous year. This results in an Earnings Per Share (EPS) of approximately (₹0.72) on a basic basis. The widening losses can be attributed to operational inefficiencies and rising costs.

**Operational Costs:** Total expenses amounted to ₹425.52 crore, up from ₹299.40 crore a year earlier, a rise of about 42.2%. Key contributors to the increased costs include higher material consumption and employee benefits expenses, indicating challenges in controlling operational costs amidst growing revenues.

**Balance Sheet & Cash Flow Statement:** The company has flagged significant defaults in loan repayments amounting to ₹3746.40 million, with all loan accounts classified as Non-Performing Assets (NPA). This raises concerns around liquidity and financial health moving forward.

**Strategic Position and Outlook:** The financial performance suggests that the company’s strategic focus remains on improving operational efficiency and managing its costs more effectively. Market sentiment appears cautious due to the outstanding debt issues and operational losses.

**Investor Insight:** Given the current financial performance and the need for prudent financial management, maintaining a 'hold' stance is advisable as the company seeks to navigate these challenges while capitalizing on growth opportunities.